LPC
MRNS

Lion Point Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Lion Point Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-693,778
Closed -$1.22M – 25
2024
Q3 		$1.22M Sell
693,778
-1,421,049
-67% -$1.98M 2.72% 10
2024
Q2 		$2.47M Sell
2,114,827
-4,309
-0.2% -$10.8K 4.51% 7
2024
Q1 		$19.2M Sell
2,119,136
-15,201
-0.7% -$148K 10.71% 3
2023
Q4 		$23.2M Sell
2,134,337
-11,000
-0.5% -$82.4K 11.61% 4
2023
Q3 		$17.3M Sell
2,145,337
-112,184
-5% -$933K 7.7% 5
2023
Q2 		$24.5M Sell
2,257,521
-362,575
-14% -$3.1M 11.08% 3
2023
Q1 		$18.1M Sell
2,620,096
-1,602,552
-38% -$10M 7.44% 5
2022
Q4 		$21.5M Buy
4,222,648
+538,026
+15% +$2.64M 3.06% 5
2022
Q3 		$19M Hold
3,684,622
– – 4.18% 8
2022
Q2 		$19M Buy
3,684,622
+55,000
+2% +$335K 2.16% 9
2022
Q1 		$33.9M Hold
3,629,622
– – 7.87% 3
2021
Q4 		$43.1M Hold
3,629,622
– – 11.56% 1
2021
Q3 		$41.3M Sell
3,629,622
-2,072
-0.1% -$28.5K 7.74% 2
2021
Q2 		$65.2M Buy
3,631,694
+13,360
+0.4% +$215K 11.26% 2
2021
Q1 		$56M Hold
3,618,334
– – 10.19% 2
2020
Q4 		$44.1M Buy
3,618,334
+900,000
+33% +$12.5M 8.5% 4
2020
Q3 		$34.9M Sell
2,718,334
-1
-0% -$9 7.66% 4
2020
Q2 		$27.6M Buy
2,718,335
+1,124,650
+71% +$10.3M 6.7% 4
2020
Q1 		$12.9M Hold
1,593,685
– – 3.41% 8
2019
Q4 		$13.8M Buy
1,593,685
+730,926
+85% +$4.1M 1.28% 16
2019
Q3 		$5.31M Buy
+862,759
New +$6.97M 0.59% 21

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lion Point Capital's MRNS Position: Q4 2024 in Review

Lion Point Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 693,778 shares — an estimated $1.22M sold.

Lion Point Capital first reported a position in MRNS in Q3 2019 and held it in 21 quarters. The position peaked at $65.2M in Q2 2021. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Lion Point Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Lion Point Capital sold 693,778 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $1.22M.
  • Lion Point Capital first reported a position in Marinus Pharmaceuticals, Inc in Q3 2019 and held it in 21 quarters.
  • Lion Point Capital's Marinus Pharmaceuticals, Inc position peaked at $65.2M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Lion Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.